← Back to Search

Immunotherapy

Viaskin Peanut 250µg for Peanut Allergy (PEOPLE Trial)

Phase 3

Waitlist Available

Research Sponsored by DBV Technologies

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Subjects who completed the PEPITES study.

Timeline

Screening 3 weeks

Treatment Varies

Follow Up month 24

Awards & highlights

PEOPLE Trial Summary

This trial is for subjects who completed the PEPITES study and are willing to receive Viaskin Peanut for 2-3 more years.

Eligible Conditions

Peanut Allergy

PEOPLE Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

PEOPLE Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ month 24

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~month 24

This trial's timeline: 3 weeks for screening, Varies for treatment, and month 24 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

% of subjects originating from the active arm of PEPITES reaching an Eliciting Dose (ED) ≥ 1,000 mg after 24 months of additional treatment in PEOPLE

PEOPLE Trial Design

1Treatment groups

Experimental Treatment

Group I: Viaskin Peanut 250µgExperimental Treatment1 Intervention

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

DBV TechnologiesLead Sponsor

16 Previous Clinical Trials

3,222 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this trial common in North American medical practices?

"Enrollment for this study is currently taking place at 23 locations. If you are interested in enrolling, it may be simplest to choose a location nearest to you from the list of participating clinics which include sites in San Diego, Chapel Hill and Pittsburgh among other places."

Answered by AI

Are we still looking for more participants for this clinical trial?

"According to the latest information from clinicaltrials.gov, this particular trial is not seeking patients at the moment. The study was originally posted on January 23rd, 2017 and updated December 1st, 2020. However, 266 other trials are actively looking for participants."

Answered by AI

Does Viaskin Peanut 250µg carry any grave risks?

"Viaskin Peanut 250µg has received a score of 3 for safety. This is due to it being a Phase 3 trial, meaning that there is both supporting efficacy data and multiple rounds of supportive safety data."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Follow-up of the PEPITES Study to Evaluate Long-term Efficacy and Safety of Viaskin Peanut in Children

2017. "Follow-up of the PEPITES Study to Evaluate Long-term Efficacy and Safety of Viaskin Peanut in Children". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03013517.